AHSP and erythroleukemia: VPA and other HDACs have been investigated for effects on hemoglobinopathies in the past and a recent preclinical study showed that 0.5 mM VPA treatment could increase Alpha Hemoglobin Stabilizing Protein (AHSP) expression in a human erythroleukemia cell line.33